Project Grant R21CA278468
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$388K
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), is focused on developing programmable, isoform-selective tools for proteome editing. Key goals of the research include: Enabling peptide-guided deubiquitination to provide "on" and "off" switches for controlling protein states in cells. Leveraging protein language models to design binders that selectively...
This Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) seeks to optimize the structure and amphiphilicity of Peptide-based Proteolysis Targeting Chimeras (PepTACs) to enhance their ability to induce targeted protein degradation through the ubiquitin-proteasome pathway. The $316,226 award will fund a 4-year research project to explore structural modifications to PepTACs that can improve...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports the development of a novel technology for light-catalyzed targeted protein degradation to selectively eliminate cancer proteins. The $218,886 award to The Trustees of Columbia University in the City of New York, effective from Jan 2, 2025 to Dec 31, 2027, aims to optimize a photocatalytic system that can initiate protein cleavage reactions to degrade target cancer proteins with high spatial...
This federal Project Grant award, valued at $849,371.00, was issued on August 2, 2024 by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research aimed at "Hijacking Post-Translational Arginylation for Targeted Protein Degradation" at the Washington University in St. Louis. The key research activities include: Applying computational techniques to identify potential ATE1 binder hits for targeted protein degradation....
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program, valued at $138,489, supports research to develop a novel "methyl arginine targeting chimera" for the lysosomal degradation of intracellular proteins. The project aims to characterize the mechanisms for applying this degradation route synthetically (Aim 1) and identify endogenous substrates of this degradation pathway (Aim 2). This research holds the potential to offer an...
The National Institute of General Medical Sciences (NIGMS) awarded a $379,131 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the University of North Carolina at Chapel Hill. The goal of this 5-year grant, effective September 1, 2024, is to develop rapid characterization strategies and predictive algorithms to guide the design of macromolecule-based therapeutics, particularly for disrupting protein-protein interactions. The research will focus on how...
The National Cancer Institute awarded a $240,092 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Scripps Research Institute in La Jolla, CA. The grant will fund research to implement a new mass spectrometry-based protein footprinting technique called Covalent Protein Painting (CPP) to measure protein conformations and protein-protein interactions in single cancer cells. The goal is to determine whether aberrant protein conformations are observed across all cells or confined to a...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $202,274 to develop an easy-to-use computer program for predicting the structure and degrading efficiency of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional molecules that induce the degradation of target proteins by recruiting them to E3 ubiquitin ligases. The awarded project aims to implement a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Duke University to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The primary objective is to translate these tumor cell-penetrating antibodies into the clinic to effectively combat aggressive human cancers driven by mutational hotspots, potentially overcoming resistance to small molecule inhibitors. Specifically, the researchers...
The National Cancer Institute (NCI) awarded a $408,829 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh to develop positive allosteric modulators (PAMs) targeting the XCR1 chemokine receptor. This research aims to enhance the function of conventional dendritic cells type 1 (cDC1s) and cytotoxic T-cell responses within the tumor microenvironment as a novel approach for cancer treatment. The project will utilize DNA-encoded library technology to screen for...